SCHEMBL1340004

SCHEMBL1340004

Cn1c(=O)c(-c2ccc(Cl)cc2)cc2c3cc(-c4csc(N)n4)ccc3n(C)c21

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LTA4H P09960 1/20 0.43
▸ GAA P10253 1/20 0.38
▸ ALDH1A1 P00352 6/20 0.37
▸ KDM4E B2RXH2 2/20 0.37
▸ CNR1 P21554 1/20 0.37
▸ CNR2 P34972 1/20 0.37
▸ SMN1; SMN2 Q16637 5/20 0.36
▸ MAPT P10636 5/20 0.36
▸ AR P10275 3/20 0.36
▸ NPC1 O15118 3/20 0.36
▸ RAB9A P51151 3/20 0.36
▸ NFKB1 P19838 1/20 0.36
▸ GFER P55789 1/20 0.36
▸ NFKB2 Q00653 1/20 0.36
▸ RELA Q04206 1/20 0.36
▸ PARP1 P09874 1/20 0.36
▸ MPL P40238 1/20 0.36
▸ MEN1 O00255 3/20 0.35
▸ KMT2A Q03164 3/20 0.35
▸ NR4A1 P22736 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1339432 0.90 CNR1 (0.40) LTA4HGAAALDH1A1KDM4ECNR1
SCHEMBL1338829 0.90 ALDH1A1 (0.47) GAAALDH1A1KDM4ESMN1; SMN2MAPT
SCHEMBL1339304 0.87 PTGS2 (0.39) GAAALDH1A1KDM4ESMN1; SMN2MAPT
SCHEMBL1338029 0.84 GABRA1 (0.41) GAAALDH1A1KDM4ESMN1; SMN2MAPT
SCHEMBL4761990 0.81 NPC1 (0.41) GAAKDM4ECNR1CNR2SMN1; SMN2
SCHEMBL1336976 0.80 TRIM24 (0.41) GAAALDH1A1KDM4ECNR1CNR2
SCHEMBL1339112 0.80 RAB9A (0.61) GAAALDH1A1KDM4ESMN1; SMN2MAPT
SCHEMBL3256818 0.79 EIF4E (0.39) GAAALDH1A1KDM4ECNR1CNR2
SCHEMBL1338822 0.79 PARP1 (0.37) GAAALDH1A1KDM4ECNR1CNR2
SCHEMBL1339161 0.79 EIF4E (0.39) GAAALDH1A1KDM4ECNR1CNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8063061-B2 6-(2-amino-1,3-thiazol-4-yl)-3-(2,4-dichlorophenyl)-1-methyl-1,9-dihydro-2H-pyrido[2,3-b]indol-2-one; affinity for GABAA-receptor-associated omega modulatory sites SANOFI-AVENTIS (FR) 2011-11-22 — — US disclosed
EP-1940840-B1 6-HETEROARYLPYRIDOINDOLONE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF SANOFI AVENTIS (FR) 2010-07-21 — — EP disclosed
US-20080262020-A1 6-Heteroarylpyridoindolone Derivatives, Their Preparation and Therapeutic Use Thereof SANOFI-AVENTIS (FR) 2008-10-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080262020-A1 6-Heteroarylpyridoindolone Derivatives, Their Preparation and Therapeutic Use Thereof CYP11B2, CYP11B1, CYP2D6 LTA4H 1171/4885GAA 1532/4885ALDH1A1 283/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback